Goldman Sachs
ZYNE

Goldman Sachs’s Zynerba Pharmaceuticals, Inc ZYNE Stock Holding History

Goldman Sachs’s Portfolio ZYNE Stock Details ZYNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-11,344
Closed -$8K – 6379
2022
Q3 		$8K Buy
+11,344
New +$12.9K ﹤0.01% 6051
2022
Q2 		– Sell
-21,726
Closed -$45K – 6837
2022
Q1 		$45K Sell
21,726
-6,945
-24% -$16.5K ﹤0.01% 6291
2021
Q4 		$83K Sell
28,671
-35,797
-56% -$132K ﹤0.01% 6175
2021
Q3 		$273K Buy
64,468
+9,586
+17% +$42.8K ﹤0.01% 5558
2021
Q2 		$290K Sell
54,882
-58,222
-51% -$280K ﹤0.01% 5538
2021
Q1 		$526K Buy
113,104
+61,080
+117% +$277K ﹤0.01% 5079
2020
Q4 		$172K Sell
52,024
-6,236
-11% -$23.7K ﹤0.01% 5138
2020
Q3 		$193K Sell
58,260
-1,531
-3% -$5.62K ﹤0.01% 4924
2020
Q2 		$201K Buy
59,791
+37,195
+165% +$176K ﹤0.01% 4793
2020
Q1 		$87K Buy
22,596
+10,014
+80% +$46.5K ﹤0.01% 4966
2019
Q4 		$76K Sell
12,582
-1,486
-11% -$10.2K ﹤0.01% 5083
2019
Q3 		$106K Buy
+14,068
New +$159K ﹤0.01% 4954
2019
Q2 		– Sell
-10,495
Closed -$57K – 5412
2019
Q1 		$57K Sell
10,495
-9,644
-48% -$46.9K ﹤0.01% 4990
2018
Q4 		$60K Sell
20,139
-5,246
-21% -$28.7K ﹤0.01% 5073
2018
Q3 		$207K Sell
25,385
-19,400
-43% -$149K ﹤0.01% 4910
2018
Q2 		$436K Buy
+44,785
New +$459K ﹤0.01% 4596
2017
Q4 		– Sell
-16,821
Closed -$141K – 6736
2017
Q3 		$141K Sell
16,821
-53,484
-76% -$565K ﹤0.01% 5926
2017
Q2 		$1.19M Sell
70,305
-10,695
-13% -$213K ﹤0.01% 4301
2017
Q1 		$1.63M Buy
+81,000
New +$1.61M ﹤0.01% 3952

Other funds holding ZYNE

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EMG
ETF Managers Group Summit, New Jersey $3.1B AUM 17.12% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
PCM
Penserra Capital Management Orinda, California $8.52B AUM 37.76% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
IEFM
IQ EQ Fund Management Dublin 2, Ireland $1.32B AUM 31.52% 1-Year Est. Return

Goldman Sachs's ZYNE Position: Q4 2022 in Review

Goldman Sachs sold out of Zynerba Pharmaceuticals, Inc (ZYNE) in Q4 2022, closing a stake of 11,344 shares — an estimated $8K sold.

Goldman Sachs first reported a position in ZYNE in Q1 2017 and held it in 19 quarters. The position peaked at $1.63M in Q1 2017. 50 funds tracked by Wall St. Rank hold ZYNE as of Q4 2022.

  • Goldman Sachs reported no remaining Zynerba Pharmaceuticals, Inc position as of Q4 2022 after selling out during the quarter.
  • Goldman Sachs sold 11,344 Zynerba Pharmaceuticals, Inc shares in Q4 2022, an estimated $8K.
  • Goldman Sachs first reported a position in Zynerba Pharmaceuticals, Inc in Q1 2017 and held it in 19 quarters.
  • Goldman Sachs's Zynerba Pharmaceuticals, Inc position peaked at $1.63M in Q1 2017.
  • 50 funds tracked by Wall St. Rank held Zynerba Pharmaceuticals, Inc as of Q4 2022.

Based on Goldman Sachs's 13F filing for Q4 2022, filed 13 Feb 2023.